close read more

Our Servier medicines

A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases.

Our medicines are prescribed in more than 150 countries worldwide. Because a drug may be marketed with different brand names in different countries, most often for legal and cultural reasons, we invite you to visit our subsidiary websites to find out what Servier products are available where you are.


A brand-name medicine, known in some languages by its Latin name, princeps, is a medicine made from an active ingredient that is being used for the first time. This active ingredient has been isolated or synthesized by a pharmaceutical company which then obtains a Marketing Authorization (MA) to sell this specific product.

In essence, it is a patent-protected “original” medicine.
Patents are titles issued by the State through the French National Institute of Industrial Property (Institut National de la Protection Industrielle – INPI). They ensure that the declared creator of an industrial invention (who submits the patent application and supporting evidence) has exclusive rights to utilize the invention for a specified period of time (usually 20 years).

It takes about ten years of Research and Development (2 years to develop new molecular entities, 3 years for preclinical trials, 5 years for clinical trials on humans) to develop a brand-name medicine, and frequently 2 more years to wade through the pertinent administrative procedures.
Consequently, when a medicinal product is finally launched on the market, the pharmaceutical company has a maximum of ten years remaining before the brand-name medicine “falls” into the public domain.

The cost of a medicine is therefore set according to the often very expensive investments made at each stage of the creation process.
This is even more remarkable considering that only one in a million molecular entities make it through research and all other subsequent stages to finally become an “original” medicine available to patients.

Last news

World Heart Day: Servier partner of the World Heart Federation campaign!
Parkinson: Servier exercises the exclusive licensing option on collaborative program with Oncodesign Precision Medicine
Servier collaborates in the treatment of pancreatic cancer